# Uncommon Therapeutics Landing Page Growth Score

Lazyweb publishes a public search API over its indexed pages; the guide is at https://www.lazyweb.com/agent-access.

Source: https://www.lazyweb.com/yc-w25/uncommon-therapeutics
Source observed: 2026-10-16T11:22:31.141Z
Last checked: 2026-10-20T08:30:54.888+00:00
Indexed: 2026-10-16T13:38:19.193+00:00

---

# Uncommon Therapeutics Landing Page Growth Score

We provide a YC W25 landing-page growth report for [Uncommon Therapeutics](https://uncommontherapeutics.com/). The report evaluates the landing page across CTA, Trust, Mobile web, Information hierarchy, and Value props.

## Overall result

- **Growth score: 47/100**
- **Updated:** Sep 23, 2026
- **Weakest category:** CTA
- **Uncommon Therapeutics ranking:** #5 in the report’s comparison set

[Fix CTA](https://www.lazyweb.com/plans/checkout?plan=individual&source=growth_score_feature_build_fixes)

### Category scores

| Category | Score | Rating shown |
|---|---:|---|
| CTA | 30 | Poor |
| Trust | 42 | Poor |
| Mobile web | 48 | Poor |
| Information hierarchy | 58 | Fair |
| Value props | 58 | Fair |

- [CTA · 30](https://www.lazyweb.com/yc-w25/uncommon-therapeutics#gs-cta)
- [Trust · 42](https://www.lazyweb.com/yc-w25/uncommon-therapeutics#gs-trust)
- [Mobile web · 48](https://www.lazyweb.com/yc-w25/uncommon-therapeutics#gs-mobile_web)
- [Information hierarchy · 58](https://www.lazyweb.com/yc-w25/uncommon-therapeutics#gs-information_hierarchy)
- [Value props · 58](https://www.lazyweb.com/yc-w25/uncommon-therapeutics#gs-value_props)

## Score over time

The report lists these tracked reports:

1. **Sep 23, 2026 — 47:** Live report; overall +2, Mobile web +6, CTA +5.
2. [Sep 3, 2026 — 45](https://www.lazyweb.com/growth-score/history/2026-09-03): First tracked report; strongest category was Information hierarchy at 58, and weakest was CTA at 25.

## CTA — 30, Poor

We assess whether copy, size, verb, and cost-feel make the primary CTA earn the click.

The comparison examples shown are:

- Acadia Pharmaceuticals: “View Our Pipeline”
- Ultragenyx: “Learn more”
- Neurogene: “GET TO KNOW OUR STORY”

The report identifies these problems for Uncommon Therapeutics:

- No CTA anywhere above the fold.
- Underlined text mimics a link but provides no action.
- The only interactive element is video pause.
- The mobile fold has zero tappable actions.

### CTA comparison

1. Acadia Pharmaceuticals — 72
2. Ultragenyx — 55
3. Neurogene — 48
4. Taysha Gene Therapies — 42
5. Uncommon Therapeutics — 30

[Rewrite this CTA](https://www.lazyweb.com/backlog?site=uncommontherapeutics.com#opt-cta-writing) with primary and secondary options grounded in Uncommon Therapeutics’s offer and visitor objections.

## Trust — 42, Poor

This category concerns proof that a product is real, competent, and safe to try.

The Uncommon Therapeutics capture includes the line **“First indication: Rett Syndrome,”** identifying a specific disease program. The comparison reads are:

| Company | Trust read |
|---|---|
| Uncommon Therapeutics | “First indication: Rett Syndrome” line naming a specific disease program |
| Taysha Gene Therapies | No visible trust signal identified. |
| Neurogene | No visible trust signal identified. |
| Acadia Pharmaceuticals | Navigation links to “Investors,” “Pipeline,” and “Healthcare Professionals,” signaling an established public pharma company |
| Ultragenyx | No visible trust signal identified. |

### Trust comparison

1. Ultragenyx — 58
2. Acadia Pharmaceuticals — 52
3. Uncommon Therapeutics — 42
4. Taysha Gene Therapies — 42
5. Neurogene — 42

[Build proof section](https://www.lazyweb.com/backlog?site=uncommontherapeutics.com#opt-trust-signals) to choose proof signals and receive copy and placement for a stronger trust section.

## Mobile web — 48, Poor

We evaluate the phone experience as a first-class experience.

![Mobile web annotations on the mobile capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/uncommontherapeutics.com-mobile.jpg?v=2026-09-23T01%3A33%3A29.07%2B00%3A00)

The annotated findings are:

1. **Eight-line hero headline:** The desktop headline scales down poorly, wrapping into eight cramped lines with no CTA below it.
2. **Strikethrough and underline styling:** The struck “rare” plus underlined “uncommon diseases” adds mid-sentence visual noise that slows reading.
3. **Bare wordmark header:** No menu icon or link accompanies the wordmark, leaving mobile visitors no visible navigation path.

[View mobile fixes](https://www.lazyweb.com/backlog?site=uncommontherapeutics.com#opt-mobile-web) to turn these findings into a prioritized implementation checklist.

## Information hierarchy — 58, Fair

![Information hierarchy annotations on the desktop capture](https://zlfyzdmohcskkucuunmk.supabase.co/storage/v1/object/public/sites/growth-score/site/uncommontherapeutics.com.jpg?v=2026-09-23T01%3A33%3A29.07%2B00%3A00)

The annotated findings are:

1. **Struck-through “rare” word:** The strikethrough-and-underline wordplay makes the headline’s final clause harder to parse at a glance.
2. **Video pause control:** The only interactive element in the fold is a pause toggle, giving it more actionability than the message itself.
3. **Wordmark-only header:** The header offers no navigation or anchor, so visitors have no orientation about what else exists on the page.

[View layout plan](https://www.lazyweb.com/backlog?site=uncommontherapeutics.com#opt-information-hierarchy) to turn these callouts into a sequenced keep, move, merge, or remove plan.

## Value props — 58, Fair

We assess whether the title, subtitle, and hero sell the product’s true value.

The report quotes the headline as:

> “Using the latest technologies to efficiently build drugs that target the underlying cause of rare uncommon diseases”
>
> “Welcome to the unCommon Era (0 uCE).”

### Working

- Names a root-cause outcome, not symptoms.
- The “rare→uncommon” strikethrough is memorable.
- States a clear mission for patients and investors.

### Could improve

- “Latest technologies” is generic filler.
- No program is named in the fold.
- The subhead is wordplay and adds no specifics.

### Value-proposition comparison

1. Ultragenyx — 68
2. Uncommon Therapeutics — 58
3. Acadia Pharmaceuticals — 58
4. Neurogene — 52
5. Taysha Gene Therapies — 42

## Competitors

The report identifies competitors as inferred from product, audience, and value proposition:

1. [Acadia Pharmaceuticals — 65](https://www.lazyweb.com/growth-score/site/acadia.com)
2. [Ultragenyx — 61](https://www.lazyweb.com/growth-score/site/ultragenyx.com)
3. [Neurogene — 52](https://www.lazyweb.com/growth-score/site/neurogene.com)
4. [Taysha Gene Therapies — 48](https://www.lazyweb.com/growth-score/site/tayshagtx.com)
5. Uncommon Therapeutics — 47
6. [Alcyone Therapeutics — failed](https://www.lazyweb.com/growth-score/site/alcyonetx.com)

---

[Read this page’s summary](https://www.lazyweb.com/api/public/v1/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-w25%2Funcommon-therapeutics&trace=t_bc7e1c4e5b07)

## Ask a follow-up about this page

Need a more specific answer? Ask the exact question you have. It returns a fresh, cited answer from Lazyweb’s knowledge base. No account or API key required.

Open this URL with your own question, URL-encoded. Only q is required. No account or setup.

`GET https://www.lazyweb.com/agent/faq?q={question}&trace=t_bc7e1c4e5b07`

[Tool guide and examples](https://www.lazyweb.com/agent-access) · [OpenAPI](https://www.lazyweb.com/api/public/v1/openapi.json) · [Page TLDR form](https://www.lazyweb.com/agent-tools/page-tldr?url=https%3A%2F%2Fwww.lazyweb.com%2Fyc-w25%2Funcommon-therapeutics). Opening a form does not execute a tool.